厄贝沙坦/氢氯噻嗪治疗轻中度原发性高血压疗效观察  

Clinical observation of Irbesartan/Hydrochlorothiazide tablets in the treatment of mild and moderate essential hypertension

作　　者：张颖 梁梅 

机构地区：[1]北京市中西医结合医院,100039

出　　处：《中国现代药物应用》2011年第10期22-23,共2页Chinese Journal of Modern Drug Application

摘　　要：目的评价厄贝沙坦/氢氯噻嗪复方片剂(依伦平)治疗轻、中度原发性高血压的临床疗效和不良反应。方法 52例轻、中度原发性高血压患者均服用依伦平8周,分别观测服药后1、4、8周的血压及用药前后生化指标的变化。结果较治疗前血压明显下降(P<0·01);降压的总效率为90·2%;舒张压<85mmHg的达标率为80·8%;血生化指标无明显变化,未观察到严重不良反应。结论厄贝沙坦/氢氯噻嗪复方片剂(依伦平)治疗轻、中度原发性高血压安全、有效,无明显不良反应。Objective To assess the clinical effect and untoward effect of Irbesartan/Hydrochlorothiazide tablets in the treatment of the mild and moderate essential hypertension.Methods 52 cases of the essential hypertension were taked Irbesartan/Hydrochlorothiazide tablets,course of 8 weeks.The changes of blood pressure after1、4、8 weeks and blood biochemical indicators were observed before and after treatment.Results Blood pressure decreased significantlyaftertreatmentcompared with before treatment（P0·01）.The total efficacy rate was 90·2%;And the control rate was 80·8%（diastolic blood pressure less than 85 mm Hg）.There were no obvious changes of blood biochemical indicators（P0·05） and rare serious untoward effect.Conclusion Irbesartan/Hydrochlorothiazide tablets is a safe,effective drug for the mild and moderate essential hypertension with rare untoward effect.

关 键 词：厄贝沙坦/氢氯噻嗪 原发性高血压 不良反应 

分 类 号：R544.1[医药卫生—心血管疾病]